SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Invest ...

文章核心观点 Axogen公司宣布将于2025年8月5日市场开盘前公布2025年第二季度财务结果，随后管理层将举办投资界电话会议和网络直播 [1] 财务信息 - 公司将于2025年8月5日市场开盘前公布2025年第二季度财务结果 [1] - 公司管理层将在财务结果发布后，于美国东部时间上午8点举办投资界电话会议和网络直播 [1] 会议参与方式 - 投资者可拨打免费电话(877) 407 - 0993或直拨电话(201) 689 - 8795参与电话会议 [2] - 投资者可访问公司网站www.axogeninc.com的投资者页面，点击网络直播链接在线收听会议 [2] - 会议结束后，公司网站投资者板块将提供会议回放 [2] 公司介绍 - 公司是专注于周围神经再生和修复技术研发与商业化的领先企业，致力于为患者恢复周围神经功能和生活质量 [3] - 周围神经损伤会导致肌肉或器官功能丧失、感觉缺失或疼痛，公司的周围神经修复平台有广泛应用，涵盖计划和紧急手术 [3] - 公司产品组合包括Avance Nerve Graft®、Axoguard Nerve Connector®等多种产品，可用于不同手术场景 [3] - 公司产品在美国、加拿大、英国、韩国及其他欧美和国际市场均有销售 [3] 联系方式 - 如需更多信息，可访问公司网站www.axogeninc.com [4] - 联系邮箱为InvestorRelations@axogeninc.com [4]

Key Takeaways WST expects Q2 revenues of $720M-$730M and EPS of $1.50-$1.55, with organic sales up 3%-4%. WST's Proprietary Products segment is set to grow 4.6%, led by GLP-1 demand and SmartDose platform gains. WST's Contract Manufacturing gains from GLP-1 injectors as CGM volume winds down and new projects ramp.West Pharmaceutical Services (WST) is scheduled to release second-quarter 2025 results on July 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Halozyme Therapeutics (HALO) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this biopharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 12.73%, on average, in the last two quarters.For the most recent quarter, Halozyme Therapeut ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

市场表现 - 道指和标普500分别上涨9点 纳斯达克上涨4点 [1] - 10年期国债收益率降至4.36% 2年期降至3.84% 30年期降至4.94% [1] 通用汽车(GM) - Q2每股收益2.53美元 超预期5.86% 营收479.8亿美元超预期1.89% [2] - 北美地区EBIT显著低于预期 股价下跌1.8% [2] 国防军工股 - 洛克希德马丁(LMT)Q2每股收益7.29美元 超预期12.33% 但营收182亿美元低于预期 股价下跌7% [3] - 诺斯罗普格鲁曼(NOC)Q2每股收益7.11美元 超预期5.96% 营收超预期2.94% 股价上涨3% [3] D.R. Horton(DHI) - Q3每股收益3.36美元 超预期15.86% 营收92.3亿美元超预期5.13% 股价上涨6% [4] - 过去一年股价累计下跌25% [4] 可口可乐(KO) - Q2每股收益0.87美元 超预期0.83美元 但营收125.4亿美元低于预期0.44% [5] - 年初至今股价累计上涨12% [5] 宣伟(SHW) - Q2每股收益3.38美元 低于预期10.11% 营收63.1亿美元超预期0.49% [6] - 股价下跌4% 年初至今转为负收益 [6] 即将公布财报公司 - 德州仪器(TXN)预计收入和利润双位数增长 [7] - Capital One(COF)预计收入和利润增长超20% [7] - Intuitive Surgical(ISRG)预计利润增长8% 收入增长16.8% [7]

市场表现 - 道指和标普500指数均上涨9点 纳斯达克指数上涨4点 [1] - 10年期国债收益率降至4.36% 2年期降至3.84% 30年期降至4.94% [1] 汽车行业 - 通用汽车(GM)Q2每股收益2.53美元超预期5.86% 营收479.8亿美元超预期1.89% [2] - 北美地区息税前利润(EBIT)低于预期 股价下跌1.8% [2] 国防工业 - 洛克希德马丁(LMT)Q2每股收益7.29美元超预期12.33% 但182亿美元营收低于预期 股价下跌7% [3] - 诺斯罗普格鲁曼(NOC)Q2每股收益7.11美元超预期5.96% 营收超预期2.94% 股价上涨3% [3] 房地产行业 - D.R. Horton(DHI)Q3每股收益3.36美元超预期15.86% 营收92.3亿美元超预期5.13% 股价上涨6% [4] - 公司股价过去一年累计下跌25% 本次上涨部分收复失地 [4] 消费品行业 - 可口可乐(KO)Q2每股收益0.87美元超预期 但125.4亿美元营收低于预期0.44% 股价小幅下跌 [5] - 公司股价年初至今仍累计上涨12% [5] - 宣伟(SHW)Q2每股收益3.38美元低于预期10.11% 营收63.1亿美元超预期0.49% 股价下跌4% [6] - 公司股价年初至今转为负收益 [6] 科技与金融行业 - 德州仪器(TXN)预计Q2利润和营收将实现两位数增长 [7] - Capital One(COF)预计利润和营收增长均超过20% [7] - Intuitive Surgical(ISRG)预计利润增长8% 营收增长16.8% [7]

GeneDx Holdings Corp. (WGS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Jul ...

The market expects Alkermes (ALKS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than ex ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Penumbra (PEN) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expectations. On ...